Type of costs | ESC (B), € | SWI (A), € | Absolute difference (B-A), € | Relative difference (B/A), % |
Treatment costs (€) + Administration costs (€) | 327,938 | 236,288 | 91,650 | 38.79% |
Monitoring costs (€) | 7335 | 6278 | 1057 | 16.84% |
Relapse costs (€) | 41,938 | 57,350 | −15,412 | −26.87% |
Adverse event costs (€) | 1472 | 913 | 559 | 61.19% |
EDSS direct costs (€) | 42,881 | 57,884 | −15,003 | −25.92% |
EDSS indirect costs (€) | 278,113 | 359,891 | −81,778 | −22.72% |
Total direct costs (€) | 421,563 | 358,713 | 62,850 | 17.52% |
Total social costs (€) | 699,676 | 718,604 | −18,928 | −2.63% |
Outcomes | ESC (B) | SWI (A) | Absolute difference (B-A) | Relative difference (B/A), % |
Total QALYs | 11.19 | 9.67 | 1.52 | 15.73% |
Total LYs | 20.10 | 19.67 | 0.43 | 2.20% |
Incremental cost-effectiveness ratio (ICER) | Escalation (B) vs. Switching (A): Cost per outcome gained | |||
QALYs (social cost) | (ESC DOMINANT) | |||
LYs (social cost) | (ESC DOMINANT) |